Partnership Opportunities

Translating MSC Exosomes into Pharmaceuticals (TEx2Pharm)

TEx2Pharm Workflow 1
"Translating MSC exosomes into pharmaceuticals" (TEx2Pharm) is a programme that aims to develop potency assays necessary to manufacture mesenchymal stem cell (MSC) exosome drugs. Exosome attributes most relevant to their therapeutic potency, or mechanism of action, will be identified and quantified for each disease target, in line with guidelines from the regulatory bodies. We are focused on four areas – cardiovascular, orthopaedic, immune and ophthalmologic diseases – all highly tractable to MSC exosomes in animal models and will further identify exosome-associated therapeutic processes in a non-biased approach through metabolomic profiling of the disease models. Exosome-associated processes will then be mapped to attributes in the exosome proteome. TEx2Pharm will evaluate the MSC exosome proteins for bioactivity and develop the potency assays required to release the drug products for clinical testing or therapeutic use.

Landmark IP

Characterisation & Potency Tests for Exosome Products:
Cytotherapy: Critical Considerations for the Development of Potency Tests for Therapeutic Applications of Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles
https://doi.org/10.1016/j.jcyt.2021.01.001
Pharmaceuticals: Assessment of Tumorigenic Potential in Mesenchymal-Stem/Stromal-Cell-Derived Small Extracellular Vesicles (MSC-sEV)
https://www.mdpi.com/1424-8247/14/4/345

Cardio Disease:
Frontiers in Cardiovascular Medicine: Systemic Mesenchymal Stem Cell-Derived Exosomes Reduce Myocardial Infarct Size: Characterization With MRI in a Porcine Model
https://www.frontiersin.org/articles/10.3389/fcvm.2020.601990/full

Orthopaedic disease:
Journal of Arthroscopic and Related Surgery: Intra-Articular Injections of Mesenchymal Stem Cell Exosomes and Hyaluronic Acid Improve Structural and Mechanical Properties of Repaired Cartilage in a Rabbit Model
https://doi.org/10.1016/j.arthro.2020.03.031

Skin disease:
International Journal of Molecular Sciences: Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation
https://www.mdpi.com/1422-0067/22/2/720

Patents
  • Mesenchymal Stem Cell Conditioned Medium
  • Mesenchymal Stem Cell Particles (Exosome)
  • MSC Exosome Biochemical Properties
  • MSC exosome restores tissue homeostasis in disease or injury
  • MSC Exosome Homeostasis (EB + GvHD)

Contact us at enquiry@bti.a-star.edu.sg

CRISP Meats: CentRe of Innovation for Sustainable banking and Production of cultivated Meats

Crisp Meats Schematic

Around the world, urban cities are exploring ways to develop sustainable food solutions to boost their food resilience. Cultivated meat has been identified as a potential novel food production modality to enable urban cities to produce food at scale and grow their food systems. CRISP Meats is an integrated platform poised to tackle some of the major challenges that the industry encounters in cultivated meat production. Hosted by BTI, in collaboration with other research entities and institutes-of-higher-learning, the programme has five workstreams to tackle the market needs in cell banking, culture media development, engineering & scaffold development. As a key player contributing to the development of cultivated meat products, CRISP Meats aims to help companies grow their businesses through R&D and create future food solutions for Singapore and beyond.  


Partnership Models

Research Collaboration Agreement

Research Collaboration Agreement v6

Research Collaboration Agreement

Under the Research Collaboration Agreement (RCA) model, A*STAR and Collaborators will jointly develop and generate new Intellectual Property (IP). Project foreground IP (FIP) that is jointly developed will be jointly owned according to intellectual input. A*ccelerate Technologies, who is the commercialization arm for A*STAR, will assist with the arrangement of Licensing Agreement, if required.

Collaborators may choose to provide cash and/or in-kind contributions in the form of consumables, equipment, and manpower. A*STAR may also contribute in-kind contributions such as equipment and manpower, where the total contributions from A*STAR will be equivalent to the cost of the project contributed by the collaborators.

Joint Laboratory Agreement

A joint laboratory agreement is an expanded RCA under which A*STAR and Collaborators co-mingle in a dedicated physical space to facilitate collaborative IP creation. Project FIP that are jointly developed will be jointly owned.

Contact us at enquiry@bti.a-star.edu.sg

License Agreement

License Agreement v6

License Agreement

Under the license agreement model, Collaborators can license A*STAR’s existing Intellectual Property (IP) for commercial purposes. A*ccelerate Technologies, who is the commercialization arm for A*STAR, will assist with the arrangement of Licensing Agreement and will facilitate the necessary technology transfer.

Contact us at enquiry@bti.a-star.edu.sg

Service Agreement

Service Agreement v6

Service Agreement

Service Agreement help companies to fulfil their project deliverables by tapping on A*STAR’s capabilities. Under the service agreement model, Collaborators pay service fees to A*STAR for deliverables based on A*STAR’s existing capabilities and proprietary background IP.

Contact us at enquiry@bti.a-star.edu.sg